Moderna reported Q1 2026 revenue of $389 million, surpassing consensus estimates, according to SEC 8-K filing.
Quarterly Results at a Glance
Revenue increased $281 million year-over-year, driven by strong international COVID-19 vaccine sales. However, a litigation settlement charge of $878 million reduced profitability, resulting in a larger net loss compared to the prior year period.
- Revenue: $389 million, up approximately 259% year-over-year
- EPS: -$3.40 per share (vs. -$2.52 in prior year quarter)
- Net loss: $1.3 billion, including $900 million litigation settlement charge
- R&D expenses: $649 million, down 24% year-over-year
- SG&A expenses: $173 million, down 18% year-over-year
- Cash and investments (as of March 31, 2026): $7.5 billion
2026 Full-Year Guidance
Moderna projects full-year 2026 revenue growth of up to 10% compared to 2025, with U.S. and international markets each representing approximately 50% of revenue. Full-year R&D expenses are estimated at approximately $3 billion, with SG&A expenses around $1 billion. Year-end cash and investments are projected between $4.5 billion and $5 billion. The $950 million litigation settlement payment is scheduled for Q3 2026. CEO Stéphane Bancel stated, "Building on actions taken in 2025, we expect to return to revenue growth."
Market Response
Moderna's stock surged following the earnings release. Yahoo Finance and StockStory noted that revenue exceeded consensus expectations. WSJ reported, "Revenue increased but losses also widened." Investing.com highlighted, "Sales beat guidance, but loss margins expanded."
Business Segment Breakdown
- U.S. revenue: $78 million
- International revenue: $311 million, representing approximately 80% of total revenue
- COVID-19 vaccine sales growth was the primary driver of total revenue expansion
- European approvals granted for combination flu-COVID vaccine 'mCOMBRIAX' and COVID vaccine 'mNEXSPIKE'
- Initial supply deliveries commenced under long-term strategic partnership in the United Kingdom
This article was auto-generated based on SEC 8-K filings and third-party reporting to provide rapid dissemination of key data following announcement. Investors are advised to review official company disclosures before making trading decisions.
